John Lincoln, MD
Neurology · Houston, TXNPI 1417121245
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $136,403 of the $197,545 with a category attached, or 69.0%. Biogen accounts for 61.3% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $56,898 and has fallen 70.4% since, to $16,816 in 2025. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $518.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$121K
- Sanofi$34K
- Novartis$10K
- EMD Serono, Inc.$7K
- Bristol Myers Squibb$6K
- Amgen$6K
- plus $13K from 17 others
Across 17 payments — averaging $19,873 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$157K
- AstraZeneca$150K
- Amgen$15K
- Sanofi US Services Inc.$8K
- Biogen$7K
- Sanofi-aventis U.S. LLC$1K
What the payments were for
- Consulting fees$49,24525%
- Speaking & faculty fees$136,40369%
- Travel & lodging$3,7652%
- Food & beverage$7,6694%
- Education$4630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 102 | $121,087 |
| Sanofi | 41 | $33,683 |
| Novartis | 49 | $10,489 |
| EMD Serono, Inc. | 30 | $7,286 |
| Bristol Myers Squibb | 23 | $6,231 |
| Amgen(2 entities) | 46 | $5,693 |
| TG Therapeutics, Inc. | 31 | $5,017 |
| E.r. Squibb & Sons, L.L.C. | 1 | $4,030 |
| AstraZeneca | 13 | $2,823 |
| Vanda Pharmaceuticals Inc. | 7 | $224 |
| Jazz Pharmaceuticals Inc. | 4 | $219 |
| Genentech USA, Inc. | 6 | $113 |
| Acorda Therapeutics, Inc | 5 | $113 |
| AbbVie(2 entities) | 5 | $105 |
| UCB, Inc. | 4 | $103 |
| Pfizer | 4 | $88 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Hospira, Inc. | 3 | $66 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Banner Life Sciences, LLC | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Eisai Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$197,545 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 20 | $736,204 |
| SolirisEculizumab | 13 | $681,166 |
| Kesimpta PenOfatumumab | 48 | $433,452 |
| CopaxoneGlatiramer Acetate | 29 | $194,503 |
| TysabriNatalizumab | 20 | $171,667 |
| VumerityDiroximel Fumarate | 20 | $163,240 |
| Dalfampridine ErDalfampridine | 215 | $133,382 |
| RebifInterferon Beta-1a/Albumin | 14 | $129,680 |
| MayzentSiponimod | 13 | $116,491 |
| ZeposiaOzanimod Hydrochloride | 11 | $98,189 |
| Dimethyl Fumarate | 19 | $88,504 |
| AmpyraDalfampridine | 15 | $64,473 |
| NuedextaDextromethorphan Hbr/Quinidine | 26 | $43,088 |
| MyrbetriqMirabegron | 60 | $35,409 |
| GlatopaGlatiramer Acetate | 11 | $29,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $2,823 | $681,16613 claims |
| BiogenTysabri, Vumerity | $121,087 | $334,90740 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $28 | $194,50329 claims |
| EMD Serono, Inc.Rebif | $7,286 | $129,68014 claims |
| NovartisMayzent | $10,489 | $116,49113 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $4,030 | $98,18911 claims |
| Acorda Therapeutics, IncAmpyra | $113 | $64,47315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.
Other neurology in Houston
- William OndoHouston$1.4M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Randolph EvansHouston$493K
- Leorah FreemanHouston$401K
- Mazen DimachkieHouston$388K
- Zsila SadighiHouston$361K
- Joseph JankovicHouston$323K
- Raja MehannaHouston$300K
- Eddie PattonHouston$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.